inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. 18 years or older. 3. no use of ivermectin prior to the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. 18 years or older. 3. no use of ivermectin prior to the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 18 years or older. no use of ivermectin prior to the study. no known history of ivermectin allergy. the patient can give his consent to take part in the study. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 18 years or older. no use of ivermectin prior to the study. no known history of ivermectin allergy. the patient can give his consent to take part in the study. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. 18 years or older. 3. no use of ivermectin prior to the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. 18 years or older. 3. no use of ivermectin prior to the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. the patient must be elder than 18 years old. 3. not previous administration of ivermectin before the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.

inclusion criteria: 1. patients with covid-19 typical symptoms (cough, fever, anosmia) present for not more than 96 hours. 2. the patient must be elder than 18 years old. 3. not previous administration of ivermectin before the study. 4. no known history of ivermectin allergy. 5. the patient can give his consent to take part in the study. 6. not current use of cyp 3a4 or p-gp inhibitor drugs such as quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat. use of critical cyp3a4 substrate drugs such as warfarin.